scholarly article | Q13442814 |
P2093 | author name string | Nick Curzen | |
Zeshan Qureshi | |||
Alex R Hobson | |||
Phil Banks | |||
P2860 | cites work | In-hospital and 1-year mortality in 1,524 women after myocardial infarction. Comparison with 4,315 men. | Q45903985 |
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | aspirin | Q18216 |
clopidogrel | Q410237 | ||
P304 | page(s) | 246-252 | |
P577 | publication date | 2009-01-01 | |
P1433 | published in | Cardiovascular Therapeutics | Q1871490 |
P1476 | title | Gender and responses to aspirin and clopidogrel: insights using short thrombelastography | |
P478 | volume | 27 |
Q46624023 | "Short" thrombelastography as a test of platelet reactivity in response to antiplatelet therapy: validation and reproducibility |
Q52903388 | Antiplatelet effects of clopidogrel and aspirin after interventional patent foramen ovale/ atrium septum defect closure. |
Q36800844 | Clinical characteristics associated with high on-treatment platelet reactivity of patients undergoing PCI after a 300 mg loading dose of clopidogrel, measured by thrombelastography |
Q48689443 | Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy |
Q38182428 | Gender and anti-thrombotic therapy: from biology to clinical implications |
Q35070799 | Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients |
Q35373683 | Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations |
Q47135592 | P2Y12 Receptor Antagonist, Clopidogrel, Does Not Contribute to Risk of Osteoporotic Fractures in Stroke Patients. |
Q89704156 | Population pharmacodynamics of cilostazol in healthy Korean subjects |
Q64926059 | Role of Gender in Dual Antiplatelet Therapy After Acute Coronary Syndrome. |
Q37664571 | The first six-month clinical outcomes and risk factors associated with high on-treatment platelet reactivity of clopidogrel in patients undergoing coronary interventions |
Search more.